PURPOSE: We describe cancer specific outcomes in patients with pT4 bladder urothelial carcinoma at radical cystectomy in a large international cohort. MATERIALS AND METHODS: We reviewed the records of 4,257 patients treated with radical cystectomy for bladder urothelial carcinoma at 12 centers. No patient received any preoperative systemic chemotherapy or radiotherapy. RESULTS: Of the 4,257 patients 583 (14%) had pT4 bladder urothelial carcinoma, of whom 83.7% were male, 85.2% had substage pT4a disease, 24.9% had positive soft tissue surgical margins, 57.8% had lymphovascular invasion and 53.5% had lymph node metastasis. Median followup was 55.0 months. Overall estimated 5-year recurrence-free and cancer specific survival was 29% (95% CI 22-32) and 31% (95% CI 25-36), respectively. On multivariate analysis female gender (p = 0.005 and p = 0.001), positive soft tissue surgical margins (p = 0.014 and p <0.001), lymphovascular invasion (p = 0.016 and p = 0.005), pT4b substage (p = 0.041 and p = 0.002, respectively) and lymph node involvement (each p <0.001) were independently associated with disease recurrence and cancer specific mortality. CONCLUSIONS: Patients with pT4 bladder urothelial carcinoma have highly variable outcomes. Features associated with metastatic tumor dissemination (ie lymph node invasion and lymphovascular invasion) and local disease burden (ie soft tissue surgical margins and pT4 substage) are associated with poor outcomes in patients with pT4 bladder urothelial carcinoma. Further research is needed to understand why female patients with pT4 bladder urothelial carcinoma have a worse outcome than their male counterparts.
PURPOSE: We describe cancer specific outcomes in patients with pT4 bladder urothelial carcinoma at radical cystectomy in a large international cohort. MATERIALS AND METHODS: We reviewed the records of 4,257 patients treated with radical cystectomy for bladder urothelial carcinoma at 12 centers. No patient received any preoperative systemic chemotherapy or radiotherapy. RESULTS: Of the 4,257 patients 583 (14%) had pT4 bladder urothelial carcinoma, of whom 83.7% were male, 85.2% had substage pT4a disease, 24.9% had positive soft tissue surgical margins, 57.8% had lymphovascular invasion and 53.5% had lymph node metastasis. Median followup was 55.0 months. Overall estimated 5-year recurrence-free and cancer specific survival was 29% (95% CI 22-32) and 31% (95% CI 25-36), respectively. On multivariate analysis female gender (p = 0.005 and p = 0.001), positive soft tissue surgical margins (p = 0.014 and p <0.001), lymphovascular invasion (p = 0.016 and p = 0.005), pT4b substage (p = 0.041 and p = 0.002, respectively) and lymph node involvement (each p <0.001) were independently associated with disease recurrence and cancer specific mortality. CONCLUSIONS:Patients with pT4 bladder urothelial carcinoma have highly variable outcomes. Features associated with metastatic tumor dissemination (ie lymph node invasion and lymphovascular invasion) and local disease burden (ie soft tissue surgical margins and pT4 substage) are associated with poor outcomes in patients with pT4 bladder urothelial carcinoma. Further research is needed to understand why female patients with pT4 bladder urothelial carcinoma have a worse outcome than their male counterparts.
Authors: Matthias May; Christian Stief; Sabine Brookman-May; Wolfgang Otto; Christian Gilfrich; Jan Roigas; Mario Zacharias; Wolf F Wieland; Hans-Martin Fritsche; Ferdinand Hofstädter; Maximilian Burger Journal: World J Urol Date: 2011-10-09 Impact factor: 4.226
Authors: Harun Fajkovic; Joshua A Halpern; Eugene K Cha; Atessa Bahadori; Thomas F Chromecki; Pierre I Karakiewicz; Eckart Breinl; Axel S Merseburger; Shahrokh F Shariat Journal: World J Urol Date: 2011-06-09 Impact factor: 4.226
Authors: Eric C Kauffman; Brian D Robinson; Martin J Downes; Leagh G Powell; Ming Ming Lee; Douglas S Scherr; Lorraine J Gudas; Nigel P Mongan Journal: Mol Carcinog Date: 2011-03-11 Impact factor: 4.784
Authors: Matthias May; Atiqullah Aziz; Sabine Brookman-May; Florian Roghmann; Joachim Noldus; Michael Rink; Felix Chun; Margit Fisch; Vladimir Novotny; Manfred Wirth; Roman Mayr; Armin Pycha; Antonin Brisuda; Björn Volkmer; Regina Stredele; Christopher Dechet; Stefan Vallo; Axel Haferkamp; Marco Schnabel; Stefan Denzinger; Jan Roigas; Christian G Stief; Christian Gilfrich; Patrick J Bastian; Jörg B Engel; Maximilian Burger; Hans-Martin Fritsche Journal: World J Urol Date: 2014-05-10 Impact factor: 4.226
Authors: Dharam Kaushik; Igor Frank; Manuel S Eisenberg; John C Cheville; Robert Tarrell; Prabin Thapa; R Houston Thompson; Stephen A Boorjian Journal: World J Urol Date: 2013-12-21 Impact factor: 4.226
Authors: Luis A Kluth; Harun Fajkovic; Evanguelos Xylinas; Joseph J Crivelli; Niccolo Passoni; Morgan Rouprêt; Andreas Becker; Evi Comploj; Armin Pycha; Sten Holmang; Amit Gupta; Yair Lotan; Pierre I Karakiewicz; Paolo Gontero; Felix K-H Chun; Margit Fisch; Douglas S Scherr; Shahrokh F Shariat Journal: World J Urol Date: 2012-11-30 Impact factor: 4.226
Authors: Ali Al-Daghmin; Eric C Kauffman; Yi Shi; Ketan Badani; M Derya Balbay; Erdem Canda; Prokar Dasgupta; Reza Ghavamian; Robert Grubb; Ashok Hemal; Jihad Kaouk; Adam S Kibel; Thomas Maatman; Mani Menon; Alex Mottrie; Kenneth Nepple; John G Pattaras; James O Peabody; Vassilis Poulakis; Raj Pruthi; Juan Palou Redorta; Koon-Ho Rha; Lee Richstone; Francis Schanne; Douglas S Scherr; Stefan Siemer; Michael Stöckle; Eric M Wallen; Alon Weizer; Peter Wiklund; Timothy Wilson; Gregory Wilding; Michael Woods; Khurshid A Guru Journal: BJU Int Date: 2014-05-22 Impact factor: 5.588